{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T04:23:18Z","timestamp":1727756598754},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,30]]},"DOI":"10.7759\/cureus.70518","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T14:57:31Z","timestamp":1727708251000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Myelin Oligodendrocyte Glycoprotein Antibody Disease in a Pediatric Patient: Clinical Presentation, Treatment Response, and Follow-Up Considerations"],"prefix":"10.7759","author":[{"given":"Ahmed","family":"Elashmawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Dazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010100","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management","volume":"22","author":"Ambrosius W","year":"2020","unstructured":"Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci. 2020, 22:100. 10.3390\/ijms22010100","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin Oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl P","year":"2017","unstructured":"Peschl P, Bradl M, H\u00f6ftberger R, Berger T, Reindl M. Myelin Oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017, 8:529. 10.3389\/fimmu.2017.00529","journal-title":"Front Immunol"},{"key":"ref3","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis","author":"Flanagan EP","year":"2024","unstructured":"Flanagan EP, Tillema JM. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis. UpToDate. Connor RF (ed): Wolters Kluwer, Philadelphia, PA; 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns TG","year":"1999","unstructured":"Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. 1999, 72:1-9. 10.1046\/j.1471-4159.1999.0720001.x","journal-title":"J Neurochem"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro M","year":"2018","unstructured":"Spadaro M, Winklmeier S, Beltr\u00e1n E, et al.. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018, 84:315-28. 10.1002\/ana.25291","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger R","year":"2020","unstructured":"H\u00f6ftberger R, Guo Y, Flanagan EP, et al.. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020, 139:875-92. 10.1007\/s00401-020-02132-y","journal-title":"Acta Neuropathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai Y","year":"2020","unstructured":"Takai Y, Misu T, Kaneko K, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020, 143:1431-46. 10.1093\/brain\/awaa102","journal-title":"Brain"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al.. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref9","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis","author":"Flanagan EP","year":"2024","unstructured":"Flanagan EP, Tillema JM. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis. UpToDate. Connor RF (ed): Wolters Kluwer, Philadelphia, PA; 2024."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2741\/1351","article-title":"Transverse myelitis: pathogenesis, diagnosis and treatment","volume":"9","author":"Krishnan C","year":"2004","unstructured":"Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004, 9:1483-99. 10.2741\/1351","journal-title":"Front Biosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo A","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, et al.. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018, 90:e1858-69. 10.1212\/WNL.0000000000005560","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan S","year":"2016","unstructured":"Ramanathan S, Prelog K, Barnes EH, et al.. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016, 22:470-82. 10.1177\/1352458515593406","journal-title":"Mult Scler"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey D","year":"2019","unstructured":"Dubey D, Pittock SJ, Krecke KN, et al.. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019, 76:301-9. 10.1001\/jamaneurol.2018.4053","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor KC","year":"2007","unstructured":"O'Connor KC, McLaughlin KA, De Jager PL, et al.. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007, 13:211-7. 10.1038\/nm1488","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48-49","author":"Karussis D","year":"2014","unstructured":"Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014, 48-49:134-42. 10.1016\/j.jaut.2014.01.022","journal-title":"J Autoimmun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner GJ","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010, 47:115-23. 10.1053\/j.seminhematol.2010.01.011","journal-title":"Semin Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda S","year":"2019","unstructured":"Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019, 19:169-76. 10.7861\/clinmedicine.19-2-169","journal-title":"Clin Med (Lond)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00843-z","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives","volume":"11","author":"Gaballa SA","year":"2021","unstructured":"Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, Abdelkader H. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021, 11:866-93. 10.1007\/s13346-020-00843-z","journal-title":"Drug Deliv Transl Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/295495-a-case-of-myelin-oligodendrocyte-glycoprotein-antibody-disease-in-a-pediatric-patient-clinical-presentation-treatment-response-and-follow-up-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T14:57:33Z","timestamp":1727708253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/295495-a-case-of-myelin-oligodendrocyte-glycoprotein-antibody-disease-in-a-pediatric-patient-clinical-presentation-treatment-response-and-follow-up-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.70518","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}